Insulin-like growth factor-I (IGF-I) and its receptor (IGF-IR) have been implicated in the pathophysiology of many human cancers, including those of hematopoietic lineage. We investigated the therapeutic potential of the novel IGF-IR tyrosine kinase activity inhibitor, NVP-AEW541, on human acute myeloid leukemia (AML) cells. NVP-AEW541 was tested on a HL60 cell subclone, which is dependent on autocrine secretion of IGF-I for survival and drug resistance, as well as primary drug resistant leukemia cells. NVP-AEW541 treatment (24 h) induced dephosphorylation of IGF-IR. NVP-AEW541 also caused Akt dephosphorylation and changes in the expression of key regulatory proteins of the cell cycle. At longer incubation times (48 h), NVP-AEW541-induced apoptotic cell death, as demonstrated by caspase-3 cleavage. Apoptosis was accompanied by decreased expression of anti-apoptotic proteins. NVP-AEW541 enhanced sensitivity of HL60 cells to either cytarabine or etoposide. Moreover, NVP-AEW541 reduced the clonogenic capacity of AML CD34 þ cells cultured in the presence of IGF-I. Chemoresistant AML blasts displayed enhanced IGF-I secretion, and were sensitized to etoposide-induced apoptosis by NVP-AEW541. Our findings indicate that NVP-AEW541 might be a promising therapeutic agent for the treatment of those AML cases characterized by IGF-I autocrine secretion.
Introduction
Insulin-like growth factor-I (IGF-I) is a small (6-8 kDa) anabolic protein, which is primarily produced by the liver and bone marrow stromal cells in response to pituitary growth hormones. IGF-I functions to stimulate a variety of cell responses including proliferation, differentiation, survival, motility and adhesion. 1 The actions of IGF-I are predominantly mediated through IGF-I receptor (IGF-IR). IGF-IR consists of two a and two b subunits. The a subunit is involved in ligand binding and is found extracellularly, whereas the b subunit spans the cell membrane and contains a tyrosine kinase domain in the cytoplasmic region. 2 On ligand interaction with the a subunit, membranebound b subunit becomes autophosphorylated, enabling docking and phosphorylation of insulin receptor substrate and Shc. As a consequence, IGF-IR activates two signaling pathways, which are of paramount importance for cell proliferation and survival, that is, the extracellular signal-regulated kinase (Erk) 1/2 and phosphoinositide 3-kinase (PI3K)/Akt networks. 3 Data from experimental models and population studies have implicated the IGF-I/IGF-IR system in different types of human cancer. 4 Several studies have shown that high levels of circulating IGF-I constitute a risk factor for breast, prostate, colon and lung cancer. 2, 3, 5 Activation of IGF-IR can play a role in transformation by promoting proliferation, metastasis and angiogenesis in solid tumors. 6, 7 As far as hematopoietic malignancies are concerned, a critical role played by IGF-I/ IGF-IR signaling has been demonstrated in multiple myeloma, where it stimulates growth and potently mediates survival. [8] [9] [10] IGF-IR has been reported to have increased expression in multiple myeloma. 11 Both the Erk 1/2 and the PI3K/Akt signaling networks are frequently activated in human acute myeloid leukemia (AML) blasts. [12] [13] [14] [15] [16] We have recently reported the isolation and characterization of a HL60 AML cell subclone, referred to as HL60AR cells (for apoptosis-resistant), characterized by autocrine production of IGF-I. 17 When compared with parental (PT) HL60 cells, HL60AR cells displayed constitutive activation of the PI3K/Akt signaling pathway, which led to enhanced proliferation, decreased apoptosis and resistance to chemotherapeutic drugs. [18] [19] [20] Although a possible role of the IGF-I/IGF-IR system in AML blast growth and drug resistance in vivo has not been clearly demonstrated so far, it could not be ruled out. Indeed, IGF-IR is expressed on AML blasts, 21 and IGF-I, alone or in combination with other cytokines, stimulated AML blast cell colony growth. 22 Different approaches have been employed to inhibit the IGF-IR function in neoplastic cells, including neutralizing antibodies, IGF-I mimetics, dominant-negative IGF-IR and IGF-IR antisense/ small interfering RNA. [23] [24] [25] [26] Another possible strategy is represented by directly targeting the tyrosine kinase domain of IGF-IR. However, selective inhibition of IGF-IR activity has been quite difficult to achieve, because of the high homology between IGF-IR and insulin receptor tyrosine kinase domain. 27 Indeed, inhibition of insulin receptor activity could lead to the development of a type-II diabetes. 28 NVP-AEW541 is a recently synthesized pyrrolo [2,3d] pyrimidine derivative, which is highly selective against IGFI-R, compared with insulin receptor and other tyrosine kinases. 29 With the above in mind, we have tested NVP-AEW541 on HL60AR cells. Here, we show that NVP-AEW541 induced apoptosis in these cells. This was accompanied by downregulation of Akt phosphorylation levels, decreased expression of cyclin D 1 , increased levels of cell cycle inhibitor p27Kip1 and diminished phosphorylation of several Akt downstream substrates. Moreover, NVP-AEW541 enhanced the effect of cytosine arabinoside (ARA-C) or etoposide in inducing apoptotic cell death of HL60 cells and decreased the clonogenic growth of AML CD34 þ cells cultured in the presence of IGF-I. We also demonstrate increased autocrine secretion of IGF-I in some chemoresistant AML cases. Our results set the stage for future IGF-I/IGF-IR-directed therapy to treat AML. (2926) . Anti-phosphotyrosine (p-Tyr, clone PY20) antibody was from BD Biosciences (Milan, Italy). Monoclonal antibody to b-tubulin was from Sigma-Aldrich (St. Louis, MO, USA). NVP-AEW541 was kindly provided by Novartis Pharma AG (Basel, Switzerland). Stock solutions were prepared in dimethylsulfoxide (DMSO) and stored at À201C. ARA-C, etoposide, recombinant human IGF-I, granulocyte-macrophage stimulating factor (GM-CSF), interleukin-3 (IL-3) and IL-6, were from Sigma-Aldrich. The enzyme-linked immunosorbent assay (ELISA) kits (for IGF-I, for IGF-IR b subunit and for phosphorylated IGF-IR (p-Tyr1135/ 1136, thereafter p-IGF-IR)) were from BioSource Europe (Nivelles, Belgium).
Materials and methods

Antibodies and chemicals
Cell culture and treatment with NVP-AEW541
HL60AR and PT HL60PT cells were routinely maintained in Rosewell Park Memorial Institute (RPMI) 1640 supplemented with 10% fetal calf serum (FCS) at an optimal cell density of 3-8 Â 10 5 cells/ml. Medium was changed every 3 days. For the experiments with NVP-AEW541, cells were cultured in medium containing 2% FCS (low serum). In preliminary experiments, we found that under these conditions, sensitivity to the drug was enhanced. Control (untreated cells) were cultured in low serum medium containing an equivalent concentration of DMSO. Final concentration of DMSO in the medium never exceeded 0.001% and had no effect on cell growth or apoptosis.
Colony assay of AML cells
Samples were obtained from patients at the Policlinico S.OrsolaMalpighi Hospital, at presentation of AML and after treatment. Informed consent was obtained from all patients before obtaining the samples, according to institutional guidelines. Bone marrow mononuclear cells were isolated by Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) density-gradient centrifugation. CD34 þ progenitor cells were then isolated using immunomagnetic cell separation (Miltenyii Biotec, Bergisch Gladbach, Germany). They were seeded at a density of 1000 per six-well plate in Methocult Methylcellulose medium (Stem-Cell Technologies, Vancouver, Canada) supplemented with 20 ng/ml each of GM-CSF, IL-3, IL-6, with or without 75 ng/ml of IGF-I. Growth factors and NVP-AEW541 were replenished after 8 days of culture. Plates were incubated for 16 days, and the number of colonies was counted in situ by light microscopy at Â 25 magnification under an Olympus CKX 41 light microscope.
Cell viability analysis by MTT assay
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) cell growth and viability kit I was from Roche Applied Science (Penzberg, Germany). Briefly, cells were plated in a 96-well plate (3 Â 10 4 cells/well, 100 ml cell suspension per well) and cultured overnight in 10% serum to allow for exponential growth of cells. Cells were then treated with NVP-AEW541 for 48 h in low serum. At the end of the treatment, 10 ml of 1 Â MTT labeling reagent was added to each well and incubated for another 4 h. The samples were solubilized with 100 ml of 10% SDS in 10 mM HCl overnight at 371C. The optical density (OD) absorbance value of each well was read on a Minireader at 570 nm. Every sample was performed in triplicate and in three independent experiments. The fraction of viable cells was calculated as follows: mean OD value treated cells/ mean OD value control cells.
Flow cytometric analysis of apoptosis
For apoptosis detection, cells were stained for intracellular cleaved caspase-3. Briefly, cells were washed with phosphatebuffered saline (PBS), fixed with Reagent 1 of the Intraprep kit, according to the manufacturer's instructions (Beckman Coulter, Miami, FL, USA), permeabilized with saponin-based Reagent 2 and incubated at 41C for 12 h with Alexa Fluor 488-conjugated anti-cleaved caspase-3 rabbit antibody (2 ml/10 5 cells). Then, they were washed with PBS, and analyzed by flow cytometry, using a FC500 flow cytometer (Beckman Coulter), equipped with CXP software.
Preparation of cell homogenates for immunoprecipitation
Cells were resuspended in 50 mM Tris-HCl, pH 7.4,. 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol bis(b-aminoethylether)-N,N,N',N',-tetraacetic acid (EGTA), 150 mM NaCl, 1% Triton X-100, containing the COMPLETE Protease Inhibitor Cocktail (Roche Applied Science) supplemented with 1 mM NaF, 1.0 mM Na 3 VO 4 , 20nM okadaic acid (lysis buffer), and homogenized by 30 passages through a 25 gauge needle.
Immunoprecipitation
Cell homogenates (1 ml, containing 500 mg of protein) were precleared by adding 5 mg of normal mouse IgG and 10 mg of 50% protein A/G agarose, followed by incubation for 1 h at 41C and centrifugation at 12 000 g for 10 min at 41C. Then, samples were incubated for 2 h at 41C under constant agitation with 5 mg of the antibody to IGF-IR b subunit. Ten micrograms of 50% protein A/G agarose was then added and incubation proceeded for 1 h at 41C under constant agitation. Immunoprecipitates were then recovered by centrifugation and washed twice in lysis buffer.
Preparation of cell homogenates for Western blot analysis
Cells (at least 2 Â 10 6 /sample) were resuspended at B10 7 /ml in 10 mM Tris-HCl, pH 7. 4, 1 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, 250 mM sucrose, 25 mM Na 4 P 2 O 7 , supplemented with the COMPLETE Protease Inhibitor Cocktail. Samples were incubated at 41C for 15 min, then centrifuged at 10 000 g for 10 min at 41C. Protein concentration on the supernatant was assayed using the protein assay kit (detergent compatible, from Bio-Rad, Hercules, CA, USA).
Western blot analysis
Protein (40 mg/sample), separated on SDS-polyacrylamide gel electrophoresis, was transferred to nitrocellulose membranes. Membranes were saturated in PBS containing 0.1% Tween-20 and 5% w/v nonfat dry milk (blocking buffer) for 60 min at 371C, then incubated overnight at 41C with the primary antibodies diluted in PBS containing 0.1% Tween-20 and 5% w/v nonfat dry milk for the monoclonals, or in PBS containing 0.1% Tween-20 and 5% bovine serum albumin for the polyclonals. After four washes in PBS containing 0.1% Tween-20, the membranes were incubated for 30 min at room temperature with the appropriate peroxidase-conjugate secondary antibodies (from Cell Signaling Technology), diluted 1:2000 in PBS, 0.1% Tween-20 and washed as described above. Bands were visualized by the enhanced chemiluminescence method (Phototope-HRP Western blot detection kit, from Cell Signaling Technology). To ensure equal loading, blots were always first probed with a mouse monoclonal antibody to b-tubulin, then stripped and reprobed. Blots shown are representative of three different experiments. The level of expression of different proteins was analyzed by using the public domain software ImageJ (a Java image processing program inspired by NIH Image for Macintosh). It can calculate area and pixel value statistics of userdefined selections. Briefly, it was performed as follows: X-ray films were scanned and saved as 8-bit gray-scale JPEG files. The percentage of measurable pixels in the image was set (and highlighted in red) by using the adjust image threshold command. The number of square pixels in the section selected (the protein bands) was then counted by measuring the area in the binary or thresholded image.
Reverse transcription-polymerase chain reaction for IGF-IR
Total RNA from HL60AR cells and CD34 þ progenitor cells from AML patients was isolated using the RNAeasy Kit (Qiagen, Valencia, CA, USA), following manufacturer's instructions. cDNA synthesis from total RNA (2 mg) was performed using MMLV reverse transcriptase (Stratagene, La Jolla, USA). cDNA (2 ml) was amplified in a 50 ml reaction volume containing 50 pmol of each primer and 45 ml of platinum super mix high fidelity (Invitrogen, Carlsbad, CA, USA). IGF-IR forward primer was 5 0 -GAAGTGGAACCCTCTC-3 0 , whereas reverse primer was 5 0 -CTTCTCGGCTTCAGTTTTGG-3 0 , as described elsewhere. 30 The cycling conditions were as follows: a 2 min enzyme activation at 941C, followed by a total of 35 cycles at 941C (30 s), 521C (30 s), 681C (1 min); final extension was performed at 681C for 5 min, on a GeneAmp PCR Systems 2400 thermal cycler apparatus (Applied Biosystems, Foster City, CA, USA). bactin was used as an internal control. b-Actin forward primer was 5 0 -TCATGTTTGAGACCTTCAA-3 0 , whereas reverse was 5 0 -GTCTTTGCGGATGTCCACG-3 0 .
Quantitative real-time RT-PCR analysis
Amplification was carried out in a total reaction volume of 25 ml in a MicroAmp Optical 96-well reaction plate (Applied Biosystems). Real-time PCR reactions were performed with TaqMan universal master mix (Applied Biosystems). Reactions were run on the ABI PRISM 7300 sequence detection system with the following thermal conditions: 951C for 10 min, followed by 45 cycles at 951C for 10 s, 601C for 15 s and 721C for 11 s. Primers sequence were: IGF-I forward 5
Quantification analysis was performed using the DDCt method and statistically analyzed by GraphPad Prism software.
ELISA assays
ELISA assays were performed according to the manufacturers instructions (Biosource Europe). For detection of IGF-I in culture supernatant of AML blasts, cells were cultured for 3 days in serum-free RPMI 1640, supplemented with 20 ng/ml each of GM-CSF, IL-3, IL-6. Briefly, cell culture supernatants (100 ml) were added to 96-well microplates, coated with monoclonal anti-IGF-I antibody, followed by 100 ml of alkaline phosphataseconjugated anti-IGF-I antibody. Incubation was for 90 min at room temperature under gentle shaking. After three washes, 100 ml of the chromogen/substrate reaction (P-nitrophenyl phosphate) was added and incubated for 30 min at room temperature. After stopping the reaction, the absorbance was read at 405 nm. Patient IGF-I concentrations were directly read from standard curves obtained with human recombinant IGF-I. For IGF-IR b subunit and p-IGF-IR analysis, cell extracts were made according to the instructions. Horseradish peroxidaseconjugated anti-rabbit IgG was employed, and the chromogen was tetramethylbenzidine. Absorbance was read at 450 nm. Values were expressed as arbitrary units.
Statistical evaluation
The data are shown as mean values7s.d. Data were statistically analyzed by a Dunnet test after one-way analysis of variance (ANOVA) at a level of significance of Po0.05 vs control samples.
Results
NVP-AEW541 induces a dephosphorylation of the IGF-1R and downregulates the PI3K/Akt, but not the Erk 1/2, signal transduction pathway
The tyrosine phosphorylation of the IGF-IR b subunit in response to NVP-AEW541 treatment was examined in HL60AR cells (Figure 1a) . IGF-IR b subunit (98 kDa) was immunoprecipitated by means of a specific antibody from whole cell extracts and blotted to nitrocellulose membranes. The blots were then probed with an antibody to p-Tyr (Figure 1a) . NVP-AEW541 induced a marked and concentration-dependent dephosphorylation of IGF-IR b subunit. In contrast, the total amount of IGF-IR b subunit was not affected by NVP-AEW541.
Our own previous results have indicated that IGF-I-mediated upregulation of the PI3K/Akt signaling network is responsible for the enhanced proliferation rate and resistance to chemotherapeutic drugs or arsenic trioxide of HL60AR cells. 17, 18, 32 Therefore, we determined whether treatment with NVP-AEW541 resulted in downregulation of PI3K/Akt signaling. Western blot analysis with an antibody to Ser 473 p-Akt, demonstrated a concentration dependent decrease in the phosphorylated Akt form in response to a 24 h incubation with NVP-AEW541 (Figure 1b) . In contrast, the amount of total Akt protein was not affected by this inhibitor. As IGF-IR also signals through the Erk 1/2 network, the outcome of NVP-AEW541 on the levels of Thr 202/Tyr 204 p-Erk 1/2 was evaluated. However, NVP-AEW541 elicited only marginal effects on the levels of activated Erk 1/2.
NVP-AEW541 affects the expression of key cell cycle regulatory proteins
Previous results have indicated that NVP-AEW541 could block neoplastic cells in the G1 phase of the cell cycle. 33, 34 In preliminary experiments, we found that NVP-AEW541 caused a concentration-dependent increase of cells in the G1 phase of the cell cycle. This was accompanied by a corresponding decrease in the percentage of cells in both S and G2/M phase (data not presented). As NVP-AEW541 increased the percentage of cells in the G1 phase of the cell cycle and downregulated PI3K/Akt signaling, the expression of targets downstream of PI3K/Akt was examined. Western blot analysis demonstrated that NVP-AEW541 induced a dephosphorylation of mTOR on Ser 2448 (which is targeted by Akt) and its downstream effector, p70S6K ( Figure 1c) . It is well known that activation of mTOR/p70S6K signaling results in enhanced translation of cyclin D 1 , which is important for cell cycle progression. 35, 36 However, the expression of cyclin D 1 is also under the negative control of GSK3b, which targets cyclin D 1 for ubiquitination and degradation. 37 Akt phosphorylates GSK3b on Ser 9 and inhibits its activity. 38 NVP-AEW541 diminished the levels of p-GSK3b (but not of total GSK3b), and this was accompanied by an increase in the levels of p-cyclin D 1 and a decrease in the expression of cyclin D 1 protein (Figure 3 ). The expression of p27Kip1 was also examined. Indeed, it is well known that PI3K/Akt signaling accelerates p27Kip1 turnover and degradation. 39, 40 NVP-AEW541 treatment of HL60AR cells resulted in enhanced levels of p27Kip1 (Figure 1c) . Thus, NVP-AEW541 inhibited GSK3b phosphorylation and led to enhanced levels of p27Kip1.
NVP-AEW541 negatively affects cell survival and induces apoptosis concomitantly with a decrease in anti-apoptotic protein expression levels
To determine whether a prolonged incubation of HL60AR cells in the presence of NVP-AEW541 would result in diminished cell survival and increased apoptosis, as reported by others, 33, 41 HL60AR cells were incubated in low serum in the presence of increasing concentrations of the inhibitor for 48 h. To evaluate cell survival, the MTT assay was employed. As shown in Figure 2a , there was a progressive decrease in cell survival at increasing concentrations of NVP-AEW541. The IC 50 was approximately 110 nM. Overall, the results obtained with NVP-AEW541 were similar to those obtained using a well established monoclonal antibody, which blocks IGF-IR a subunit (Figure 2b ). 33 We next investigated whether decreased survival was related to apoptosis. It is well known that a distinguishing feature of apoptotic cell death is the activation of a family of proteases referred to as caspases, 42 which are responsible for most of the biochemical and morphological changes which distinguish this type of cell death. HL60AR cells were immunostained with an Alexa Fluor 488-conjugated antibody, which selectively reacts with the cleaved form of caspase-3, one of the effector caspases. The antibody detects endogenous levels of the large fragment The expression of some survival proteins was analyzed next. NVP-AEW541 markedly diminished the levels of XIAP, survivin, Bcl-X L , FLIP-L and Mcl-1 (Figure 3c) . XIAP, Bcl-X L and FLIP-L were already markedly downregulated at 60 nM NVP-AEW541, although Mcl-1 and, most of all, survivin required 100 nM NVP-AEW541 to be significantly downregulated.
NVP-AEW541 increases HL60AR cell sensitivity to ARA-C and etoposide
Previous results have highlighted that constitutive activation of the PI3K/Akt pathway in HL60 AR cells contributes to chemoresistance. 17 Moreover, others have demonstrated that NVP-AEW541 enhanced sensitivity of cancer cell lines to chemotherapeutic agents including vincristine and cisplatin. 33, 41 Therefore, NVP-AEW541 was combined with ARA-C, which is widely used for the treatment of AML, and the combination of drugs was tested on HL60AR cells. The capacity of these drugs, either alone or in combination, to induce apoptotic cell death was examined. Apoptosis was analyzed by flow cytometric analysis of samples stained with the antibody to active caspase-3 ( Figure 4a ). After a 48 h incubation period, a NVP-AEW541 concentration below the IC 50 (i.e. 100 nM) was as effective as 80 mg/ml ARA-C. However, when ARA-C (20 mg/ml) was combined with NVP-AEW541 (100 nM), a strong enhancement was obtained, as apoptotic cell death was approximately 80%. Similar results were obtained when etoposide was combined with NVP-AEW541 (Figure 4b ). These data confirmed the key role played by IGF-I/IGF-IR signaling in attenuating anticancer drug responsiveness in HL60AR cells and emphasized the potential usefulness of IGF-IR inhibitors in enhancing the antitumor activity of conventional chemotherapeutic drugs.
IGF-IR mRNA is expressed in CD34 þ cells from AML patients
The cellular expression of IGF-IR mRNA was analyzed next by RT-PCR. As expected, HL60AR cells expressed the receptor mRNA for IGF-IR (Figure 5a ). IGF-IR mRNA was then analyzed in bone marrow CD34 þ cells from five patients with AML. Expression of IGF-IR receptor transcript was also found in progenitor cells from all the five AML patients (Figure 5a ), in agreement with previous studies. 21 
IGF-I and NVP-AEW541 effects on clonogenic growth of CD34 þ hematopoietic progenitors from AML patients
Having established that AML blasts express IGF-IR mRNA, the ability of IGF-I to increase the colony growth of leukemic CD34 þ cells in semisolid culture was determined. CD34 þ cells were separated from the bulk of the AML blast population by immunomagnetic beads, and then they were either cultured in standard medium (which contains GM-CSF, IL-3, IL-6) or in standard medium supplemented with IGF-I (75 ng/ml). Addition of NVP-AEW541 to standard medium did not significantly affect the growth of colonies (Figure 5b ). In contrast, addition of IGF-I resulted in an approximately 30% increase in the number of cell colonies, in agreement with others. 22 The stimulating effect of IGF-I was almost completely blocked by addition of NVP-AEW541. In contrast, colony-forming activity of CD34 þ cells from healthy donors was not affected by the drug (data not shown). These results demonstrated that IGF-I can positively influence the clonogenic growth properties of CD34 þ cells from AML patients, and that NVP-AEW541 is efficacious in preventing proliferative effects of IGF-I.
IGF-I autocrine secretion is increased in chemoresistant AML blasts
The HL60AR cell line is a subclone which was obtained after exposure of PT cells to chemotherapeutic agents. 21 To investigate whether increased IGF-I secretion was present in chemoresistant AML cells, the expression of IGF-I was examined by real-time RT-PCR and ELISA in nine AML patient samples obtained before and after chemotherapy (Table 1 ). In four out of nine patients, there was a significant increase in both IGF-I gene activation and IGF-I secretion in tissue culture medium ( Figure  6a and b) . In contrast, IGF-II autocrine secretion was not detected in AML blasts kept in culture (not shown). IGF-IR receptor was phosphorylated on tyrosine residues (1135/1136) of the b subunit, which are key determinants of receptor catalytic subunit 43 ( Figure 6c ). In contrast, the response to chemotherapeutic treatment was not because of an increase in (Figure 6d ). These findings demonstrated that in some chemoresistant AML cases, there was an enhanced expression of the IGF-I gene which then resulted in higher levels of IGF-I autocrine secretion and IGF-IR tyrosine phosphorylation.
NVP-AEW541 sensitizes chemoresistant AML blasts to etoposide-induced apoptosis
Next, we investigated whether NVP-AEW541 (1 mM) was capable of sensitizing chemoresistant AML cells to etoposide (20 mM). NVP-AEW541 alone was capable of significantly reducing survival of chemoresistant AML blasts characterized by increased levels of IGF-I secretion (cases 2 and 6), whereas its effects were less in cases 3 and 8 (Figure 7a) , in which the secretion of IGF-I was not increased. NVP-AEW541 strongly enhanced etoposide in causing a decrease of cell survival in cases 2 and 6, whereas in cases 3 and 8, the effect of the combination treatment was only additive. Western blot analysis revealed that NVP-AEW541 effectively downregulated p-Akt in two chemoresistant AML cases (2 and 6). Cases 3 and 8, despite being chemoresistant, did not display sizable Akt activation (Figure 7b) . Moreover, as shown in Figure 7c , the decreased cellular survival rate of cases 2 and 6 was most likely owing to apoptotic cell death, as exemplified by caspase-3 activation detected by flow cytometry in case 2.
Discussion
In the present study, we provide evidence that the highly specific IGF-IR tyrosine kinase inhibitor NVP-AEW541 potently inhibited the growth of a HL60 cell subclone characterized by autocrine IGF-I secretion. It should be emphasized that we routinely grew HL60AR cells in 2% serum, as at this serum concentration the effects of NVP-AEW541 were more marked than at 10% serum. Indeed, if cells were grown in 10% serum, the IC 50 of NVP-AEW541 was considerably higher, around 3.5 mM (data not shown). Most likely, at this concentration other growth factors, present in calf serum, stimulate prosurvival signaling pathways and this lowers the efficacy of NVP-AEW541. Results similar to those obtained with 2% serum were obtained if cells were cultured with no serum (not presented).
Treatment of HL60AR cells with NVP-AEW541 resulted in downregulation of IGF-IR b subunit tyrosine phosphorylation, whereas the levels of total IGF-IR protein were unaffected. Thus, our results are in agreement with the findings of others who employed NVP-AEW541 to treat human Ewing's sarcoma cells. 33 NVP-AEW541 blocked phosphorylation of Akt, a downstream target of IGF-IR signaling. In contrast, Erk 1/2 activation was not affected by this inhibitor. This is at variance with what has been reported for Ewing's sarcoma cells lines 33 and might depend on the fact that in HL60AR cells Erk 1/ 2 activation does not occur after IGF-I secretion.
Our findings demonstrate that downregulation of IGF-IR tyrosine kinase activity for 24 h, resulted in changes in the expression and/or phosphorylation levels of several proteins which are key regulatory elements of the progression through the G1 phase. They include mTOR, p70S6K, GSK3b, cyclin D 1 and p27Kip1. These regulatory proteins are downstream targets of Akt, and this further emphasizes the importance of Akt downregulation for eliciting the effects of NVP-AEW541 on cell cycle. Although others have demonstrated that NVP-AEW541 blocks cells in the G1 phase of the cell cycle, 33, 34 this is the first report which has addressed the issue of how NVP-AEW541 might affect cell cycle regulation. NVP-AEW541 downregulated cell survival and induced apoptosis, as demonstrated by flow cytometric analysis of samples stained with an antibody to cleaved (active) caspase-3. The IC 50 value of NVP-AEW541 on HL60AR cells was approximately 110 nM. A submicromolar IC 50 value has also been reported for Ewing's sarcoma cell lines, 33 although in epithelial ovarian cancer and hepatocellular carcinoma cell lines, much higher concentrations of NVP-AEW541, in the range of 2-15 mM, were necessary to inhibit proliferation and induce apoptosis. 34, 41 This indicates that HL60AR cells have a high degree of dependency on IGF-IRelicited signaling for their proliferation and survival. Apoptosis elicited by NVP-AEW541 was accompanied by a decrease in the amount of several anti-apoptotic proteins, such as XIAP, survivin, Bcl XL , FLIP-L and Mcl-1. These proteins are capable of antagonizing caspase activation, thus blocking apoptotic cell death. 44 It is well known that IGF-I positively affects the expression of Bcl-2 family proteins such as Bcl-X L and Mcl-1. 45 This effect could be related to Akt activation, because it has established that in hematopoietic cells, the expression of these proteins is under the control of the PI3K/Akt axis. 46 Indeed, Mcl-1 and Bcl-X L genes are regulated by means of Ca 2 þ /cAMP response element binding protein (CREB) transcription factor, which can be activated through phoshorylation by Akt. Nevertheless, XIAP, survivin and FLIP-L expression could be also controlled by the PI3K/Akt pathway through the NF-kB transcription factor 45 which is frequently activated in AML. Given that our previous results highlighted the importance of Akt activation for determining drug resistance of HL60AR cells, 17 we investigated if NVP-AEW541 would increase ARA-C or etoposide sensitivity of these cells. The combination treatment consisting of a sub-IC 50 concentration of NVP-AEW541 plus ARA-C or etoposide, resulted in more than doubling of the pro-apoptotic effect which was achieved by monotherapeutic approaches with either agent. Others reports have highlighted the capacity of NVP-AEW541 to synergize with chemotherapeutic drugs such as doxorubicin, docetaxel and vincristine. 33, 34 Moreover, our investigation demonstrated that the IGF-IR is expressed on AML CD34
þ cells and addition of IGF-I to culture medium significantly increased the clonogenic capability of these cells. This increase in clonogenic growth could be completely blocked by addition of NVP-AEW541. In this set of experiments IGF-I was employed at 75 ng/ml, as reported previously. 22 Although at present there is no information about the IGF-I levels in the serum or in the bone marrow microenvironment of AML patients in vivo, our in vitro experiments have shown that the supernatants from cultured AML blasts could contain IGF-I concentrations which, in some cases, are not too much lower than 75 ng/ml (see cases 5 and 6 of the chemoresistant patients).
NVP-AEW541 displayed a 27-fold inhibitory selectivity for the IGF-IR vs the insulin receptor 29 and is slightly more active and selective than another pyrrole [2,3d] pyrimidine derivative that was recently studied in a series of tumor cell lines. 10 NVP-AEW541 has the advantage of being an orally bioavailable tyrosine kinase small molecule inhibitor and, at the concentrations employed in this study, should not result in diabetes, which is one of the most feared side-effects of blocking IGF-IR, given its structural similarities to the insulin receptor. It is now generally accepted that IGF-I attenuates the response of cancer cells to several chemotherapeutic agents. 6, 7 Thus, inhibition of IGF-I action could be a useful adjuvant to cytotoxic chemotherapeutic drugs and could allow the use of lower drug concentrations. Our results also hint at the possibility that IGF-I plays an important role in determining drug-resistance of AML blasts, because we found that in some chemoresistant AML cases, there was an increased IGF-I autocrine secretion and that NVP-AEW541 strongly enhanced etoposide effects, diminishing cell survival in these cases. It should be pointed out that for these experiments, we employed NVP-AEW541 at 1 mM concentration because in preliminary experiments we found that the IC 50 of the inhibitor, when used alone, was around 2.0 mM (data not shown). This finding highlights that higher concentrations of the inhibitor are required to inhibit AML blast growth when compared to HL60AR cells. At present, the reason for this different requirement is unclear. Nevertheless, even at this higher concentration, NVP-AEW541 retains its specificity for the IGF-IR and should not inhibit the insulin receptor kinase activity, 29 thus avoiding the possible onset of type-II diabetes, which is one of the most feared side effects of IGF-IR blockage.
Autocrine/paracrine secretion of other growth factors, such as vascular endothelial growth factor and fibroblast growth factor, have also been reported to be a determinant of survival and resistance to chemotherapy in AML cells. 48, 49 Moreover, it should be emphasized that the HL60AR cell subclone we employed for this study is drug resistant. 17 Interestingly, a recent report has highlighted that IGF-I expression levels are higher in AML patients in the refractory stage, after ARA-C combined chemotherapy, than those in patients at diagnosis. 50 Therefore, those results and our own findings strongly suggest that the inhibition of IGF-IR and its downstream signaling pathways might be a valuable therapeutic approach to overcome drug resistance in some AML cases characterized by enhanced autocrine secretion of IGF-I.
